Greentown Labs announced its latest accelerator program — this one is focused on DEI in clean energy innovation. Photo via GreentownLabs.com

Greentown Labs has announced its latest accelerator program that will be co-located in both its Houston and Boston-area spaces.

In partnership with Browning the Green Space, Greentown Labs has officially launched the Advancing Climatetech and Clean Energy Leaders Program, or ACCEL, and is seeking applications from climatetech entrepreneurs who identify as Black, Indigenous, and/or People of Color.

The startups accepted into the year-long program will receive a curated curriculum, incubation at one of the Greentown locations, and mentorship from its large network of energy professionals. Each participant will also receive a non-dilutive $25,000 grant. Applications for ACCEL are open now and are due by Dec. 23

“We need all hands on deck to solve the climate crisis and foster a just energy transition,” says Emily Reichert, CEO of Greentown Labs, in a news release. “We are proud to partner with Browning the Green Space on this important program, and are eager to support more underrepresented founders through ACCEL to help build a more diverse, inclusive, and equitable climatetech industry.”

BGS is a nonprofit that is focused on making clean energy other climate-related fields more diverse, equitable, and inclusive. The organization is headquartered in Boston.

“We are excited to work in partnership with Greentown Labs to build critical support infrastructure for entrepreneurs of color and accelerate the equitable development and distribution of climate solutions across all communities,” says Kerry Bowie, executive director and president of Browning the Green Space, in the release. “ACCEL will help us move closer to where we all should be collectively, and create the opportunity to change the face of clean energy as we know it.”

The new program is also supported the Massachusetts Clean Energy Center, a state economic development agency dedicated to accelerating the growth of the clean energy sector across the Commonwealth, and then Boston-based Barr Foundation, a foundation with a regional focus, working in partnership with partners to elevate the arts, advance solutions for climate change, and connect all students to success in high school and beyond, per the news please.

“The Barr Foundation’s climate program has made a commitment to centering racial equity in the energy transition,” says Kathryn Wright, senior program officer of Clean Energy at The Barr Foundation, in the release. “We are excited to support this crucial opportunity to provide education and mentorship for underrepresented climate entrepreneurs in our region. We look forward to seeing the impact of the ACCEL program in the coming years.”

The curriculum for ACCEL will be led by Hadley, Massachusetts-based VentureWell, a nonprofit that funds and trains innovators to create successful, socially beneficial businesses. Applicants may be based anywhere in the world, but will be expected to attend in-person elements of the program at either Greentown Boston or Greentown Houston.

The five finalists in the BIPOC and Female-Founded Business categories for the Houston Innovation Awards share the challenges they have had to overcome. Photos courtesy

Overheard: Houston-based BIPOC, female founder finalists of 2022 share challenges overcome

eavesdropping at the houston innovation awards gala

Houston is often lauded as one of the most diverse cities in America, and that diversity is seen across its business communities as well, which includes its innovation ecosystem.

Some of the BIPOC-Founded and Female-Founded Business category finalists from the Houston Innovation Awards Gala, which will be held on November 9, shared some of the challenges they faced being in the minority of their industries and careers.

"The biggest challenge I've faced as a female BIPOC founder is having to work 2 to 4 times harder to convince individuals that I am an expert in my field, and that I know what I'm talking about when it comes to my technology and implementation."

Photo courtesy

— Asma Mirza, CEO and co-founder of Steradian Technologies. "The way I overcame it was by showing irrefutable data to support my expertise and our invention, as well as hiring a diverse team that could substantiate our claims," she adds.

"As a female founder, I used to think that I was looked at as 'less than,' compared to my male counterparts. While I still struggle with this feeling,...  I decided that the biggest hinderance in my confidence as a female founder was the lies that I was telling myself."

Photo courtesy

— Megan Eddings, founder of Accel Unite. "I felt — and still sometimes do — insecure in a room filled with male founders, not because I thought I was any less-than, but because I was thinking they thought I was less-than — before ever even meeting me," Eddings added, sharing how she tries to change her own perspective. "I now feel a responsibility to share my story, as to show other women that they are not alone, their voice matters and to keep going."

"As a BIPOC founder, it was not easy in the beginning to find the connections and network with folks that had the resources to help us with our aspirations. That was the biggest challenge in getting started."

Photo courtesy

— Enrique Carro, CEO of Blue People. "Now that we have a few clients and testimonials, we are able to pull on them to help us find new clients and connections," he continues. "But this was something that we had to really work hard on at the beginning."

"One of my fears going into the fundraising process was being seen as too weak or too fragile to lead an early-stage venture."

Photo courtesy

— Joanna Nathan, CEO of Prana Thoracic, who shares she feels this way following the loss of her son. "I found that in being transparent with potential investors, after building some trust, and speaking openly about my loss and how it has inspired me to build this company, I was able to overcome this fear."

"The biggest challenge I’ve faced as a female founder comes down to resources. Finding the capital and time to get everything done is difficult for female founders because we have a lot on our shoulders and there are systemic inequalities that make things even more difficult."

Photo courtesy

— Allie Danziger, founder and CEO of Ampersand. "I’m creating a billion dollar company, but I’m a mom of two young girls, the executive director of one nonprofit and a board member of another, and a dependable friend, wife, daughter, sister and niece, too," she continues. "Other female founders and VCs are stretched, too, so it can be difficult to connect and find time to figure it out together. I have been very fortunate and also worked really hard to find both the time and resources to make it all work."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.